ArticleDiscover oncology2026
Molecular characterization of mismatch repair deficient tumors in young Jordanian patients.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mismatch repair deficiency (MMRD) contributes substantially to early-onset colorectal carcinoma (CRC) and pediatric malignancies in Jordan. Approximately 19% of CRCs diagnosed in adults younger than 45 years exhibit MMRD by immunohistochemistry (IHC). In pediatric tumors, MMRD accounts for 39% of high-grade gliomas (HGGs) and 44% of CRCs, likely reflecting the increased prevalence of constitutional MMRD (CMMRD) in this highly consanguineous population. However, the molecular characterization of MMRD-associated tumors in the Middle East remains limited. We analyzed 14 Jordanian patients (< 45 years) from 12 families with clinical or IHC evidence of MMRD, including four HGGs and 11 CRCs; five patients were children. Pathogenic or likely pathogenic MMR variants were identified in nine families, including one sibling pair, comprising five frameshift indels, three single nucleotide variants, and one large deletion. A variant of uncertain significance in MSH6 was identified in another sibling pair. Apparent large deletions suggestive of sequencing artifacts in six patients highlighted the need for confirmatory copy number analysis by multiplex ligation-dependent probe amplification. Tumor mutational burden ranged from 2 to 352 variants/Mb (median, 23). Microsatellite instability was low in seven tumors, likely reflecting degraded DNA from older formalin-fixed paraffin-embedded samples. Mutational signatures were concordant with the molecular findings in most cases. Notably, the only ultrahypermutated tumor harbored a canonical somatic POLE p.(Val411Leu) proofreading-domain mutation together with polymerase-associated mutational signatures, consistent with combined MMRD and polymerase proofreading deficiency. This study represents the first comprehensive molecular characterization of MMRD-associated tumors in Jordan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.